The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Outpatients of either gender, age > 18
Willing and able to give informed consent and adhere to visit/protocol (Consent must be given before any study procedures are performed.)
Subject has no diagnosed pulmonary conditions
Subject has not smoked in the previous 5 years
MRI is contraindicated based on responses to MRI screening questionnaire
Subject is pregnant or lactating
Resting O2 saturation <90% with maximum supplemental O2 delivered by nasal canula
Respiratory illness of a bacterial or viral etiology within 30 days of MRI
Parallel
Hyperpolarized Xe129
DrugHyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
Oxygen Administration
Other interventionOxygen administration
Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis
The investigators will validate the Hb (hemoglobin) correction model in anemia patients pre/post transfusion and blood donors pre/post apheresis.
Change in RBC (red blood cell) Chemical Shift After Oxygen Administration
To test the effects of oxygen on 129Xe MRI/MRS in healthy subjects, those with ILD, those with dyspnea, and patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Change in RBC Oscillation Amplitude Post Therapy
Patients with chronic PE are treated surgically and those with acute PE are treated with anticoagulation therapy.
Click on the lead sponsor to view all of their trials.
Bastiaan Driehuys
Lead sponsor
Duke University
Sponsor institution
National Institutes of Health (NIH)
Collaborator
